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RESEARCH NOTE
Evaluation of serum iron overload, 
AST:ALT ratio and  log10ferritin:AST ratio 
among schizophrenia patients in the Kumasi 
Metropolis, Ghana: a case–control study
W. K. B. A. Owiredu1, Peter Kojo Brenya1, Yaw Osei3, Edwin Ferguson Laing1, Clement Opoku Okrah4, 
Christian Obirikorang1, Enoch Odame Anto1,2, Emmanuel Acheampong1,2 and Sampson Donkor1* 
Abstract 
Objective: The association between unbalanced iron indices and the conditions of schizophrenia are not well under-
stood. Liver dysfunction which has been linked to iron metabolism might be a contributing factor. This case–control 
study evaluated serum iron indices and liver function in treatment-naïve schizophrenia patients and those already on 
treatment at the Psychiatric Department of the Komfo Anokye Teaching Hospital (KATH), Kumasi-Ghana.
Results: The mean age of the respondents was 39.6 ± 0.8 years. Increased levels of serum iron, TS, AST, ALT and 
AST:ALT ratio and lower levels of UIBC, TIBC, Transferrin, and log Ferritin:AST ratio levels were observed among the 
treatment-naïve group compared to the control. The treatment-naïve and treatment groups showed significantly 
higher serum AST:ALT ratio, and lower  log10ferrtin:AST ratio than the healthy controls. There was a significant correla-
tion between  log10ferritin and AST, and  log10ferritin and GGT in both treatments (r = 0.343; p = 0.003, and r = 0.502; 
p = 0.001 respectively) and treatment-naïve groups (r = 0.348; p = 0.002, and r = 0.614; p < 0.001 respectively). Percent-
age transferrin saturation correlated significantly with GGT only, in the treatment-naïve group (r = 0.667; p < 0.001), 
and ALT and GGT in the treatment group (r = 0.252; p = 0.030 and r = 0.646; p = 0.014 respectively).
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Introduction
According to the World Health Organization (WHO) 
[1], mental disorders account for five of the ten leading 
causes of disability and premature death worldwide, of 
which neuropsychiatric condition accounts for 13% of 
the total disability adjusted life years [1]. A prevalence 
based rate report from the World Mental Health Survey 
2004, undertaken by WHO in Ghana estimated that, 13% 
of the adult population suffer from some form of mental 
disorder [2].
Studies in Ghana have indicated that schizophrenia is 
the leading psychiatric condition [3, 4]. Owiredu et  al. [5] 
in their study in Ghana reported a prevalence of 59% for 
schizophrenia compared to other psychiatric conditions [5]. 
Serious mental illness is accompanied by higher morbidity 
and mortality rates of chronic diseases such as lung disease, 
diabetes and liver problems [6]. A previous study found that 
liver dysfunction is particularly elevated in adults with men-
tal illness [7]. Iron overload has been reported to be signifi-
cantly associated with liver damage [8].
Iron overload (IO) has been reported to be associated with 
parenchymal and organ dysfunction following abnormal 
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deposition of tissue iron [9, 10]. Dangers of IO in several 
disease conditions over the years including coronary disease 
[10–12], diabetes mellitus [10, 13], sexual impotence [9, 10], 
cerebral ischemic disease [10, 14] and neurologic or psychi-
atric alterations [10, 15] has been noted.
The manifestations of neuropsychiatric effects of 
chronic iron overload have been observed in depressives, 
memory loss, paranoia, visual hallucination, lethargy, 
disorientation, dementia, and anxiety symptoms [16, 17]. 
However, the pathophysiology of iron metabolism in psy-
chiatric illnesses still remains unclear, albeit several stud-
ies have suggested a possible link between serum iron 
and some variables in psychiatric conditions [16, 18].
There is dearth of data on  serum iron indices among 
psychiatric patients in Ghana, and the association 
between iron overload and primary psychiatric illness. 
Also, little is known about the liver function of psychi-
atric patients in Ghana. This study therefore evaluated 
serum iron indices and liver function among schizophre-
nia patients in a Ghanaian population.
Main text
Methods
Study population and setting
This case–control study was carried out at the Psychiat-
ric department of the Komfo Anokye Teaching Hospital, 
Kumasi-Ghana. Qualifying patients attending the psychi-
atric department were recruited into the study using Inter-
national classification of Diseases (ICD-10). Healthy control 
participants were recruited from a keep fit club. A total of 
200 participants comprising 75 treatment-naïve schizophre-
nia patients, 75 schizophrenia patients on treatment and 50 
healthy controls were recruited via purposive sampling.
Ethical consideration
The study was approved by the Committee on Human 
Research, Publications and Ethics (CHRPE), and the 
Research and Development Unit of the Komfo Anokye 
Teaching Hospital (KATH). Written informed consent 
was obtained from each participant through their legally 
authorised family members before enrolment into the 
study. All data obtained from participants was held under 
strict confidentiality.
Inclusion criteria
Newly diagnosed naïve schizophrenia patients and those 
already on any form of antipsychotic, such as olanzapine, 
haloperidol, risperidone etc., were included in the study. 
Age and sex-matched healthy individuals who were not 
on any medication (antibiotics, vitamins supplement), 
non-alcoholic, Tuberculosis free, HIV free, Hepatitis B 
virus free, and were not presenting any signs of chronic 
illness were included in the study. All respondents 
were ≥ 18 years.
Exclusion criteria
Schizophrenia patients already on iron therapy, non-ste-
roidal anti-inflammatory agents, antacids, alcohol con-
sumption, pain killers such as paracetamol etc., multiple 
blood transfusions and androgen/oestrogen therapy were 
all excluded from the study.
Questionnaire administration and sample collection
A validated questionnaire was administered to all 
respondents by qualified nurses to collect demographic 
data including age and gender. About 4  ml of venous 
blood sample was collected from the antecubital fosa of 
the study participants after an overnight fast, and sera 
were obtained after centrifugation.Assayparameters 
included: serum iron, unsaturated iron binding capacity 
(UIBC), total iron binding capacity (TIBC), transferrin, 
ferritin, percentage transferrin saturation, aspartate ami-
notransferase (AST), gamma glutamyl transferase (GGT) 
and alanine aminotransferase (ALT). AST, GGT and ALT 
were performed on a fully automated Mindray BS-380 
auto-analyzer (Shenzhen Mindray Bio-medical electron-
ics Co., Ltd, China). Ferritin was performed on  Mindray® 
microplate reader MR 96 A. The assay for UIBC and 
iron were performed on the Mindray BA-88A Biochem-
istry auto-analyzer. Transferrin concentration was esti-
mated according to Vernet [19] and Gambino et al. [20] 
equation.
Statistical analysis
Results are presented as mean ± SD. Analysis of variance 
(ANOVA) coupled with Tukey’s post hoc multiple com-
parisons was used to compare more than two means of 
continuous variables. Unpaired t-test was used to com-
pare the means of two continuous variables. Chi-square 
test was used to assess the associations between cat-
egorized variables. Partial Pearson correlation was per-
formed to test for associations between iron indices and 
liver function markers. A p-value < 0.05 was considered 
statistically significant for all analyzed data. Statistical 
analyses were performed using GraphPad Prism 7.
Results
Table  1 shows demographic characteristics of age and 
gender of the study participants. Out of the total 200 
participants, 104 (52%) were females and 96 (48%) 
were males. The mean age of the study population 
was 39.6  years. There was no significant difference 
between the mean age of the control group compared 
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to the treatment (p = 0.4654) and treatment-naïve group 
(p = 0.4120).
Serum iron concentration and percentage transferrin 
saturation were significantly higher in treatment-naïve 
psychiatric patients compared to the control (p < 0.0001). 
Mean levels of transferrin, UIBC and TIBC was signifi-
cantly lower in treatment-naïve psychiatric patients com-
pared to the control (p < 0.0001). The levels of serum 
ferritin was highest among the treatment-naïve group, 
followed by the treatment group, and did not differ sig-
nificantly compared to the control. Generally, the treat-
ment-naïve group recorded the highest mean AST, ALT 
and GGT levels, followed by the treatment group. There 
was a statistically significant difference between the AST 
and GGT levels of the treatment-naïve group and that of 
the control group (p = 0.0035 and 0.0418 respectively). 
Both the treatment-naïve and treatment groups had 
higher mean AST:ALT ratio (1.61; p = 0.0004 and 1.50; 
p = 0.0282 respectively) than the control group (1.29). 
However, mean log ferritin:AST ratio decreased signifi-
cantly from the control (0.096) to treatment group (0.084, 
p = 0.0448) and then to the treatment-naïve group (0.080; 
p = 0.0113) (Table 2).
Table 3 shows the biochemical profile of the study pop-
ulation stratified by gender. There was no statistical dif-
ference between any biochemical parameter and gender 
among the control group. Both males and females in the 
treatment and treatment-naïve groups reported higher 
mean levels of iron, transferrin saturation, ALT, GGT 
and AST but lower levels of UIBC rather  than the con-
trol group. The male respondents of the treatment-naïve 
group showed significantly higher mean serum iron, 
Table 1 Demographic characteristics of the study participants
Values are presented as mean ± standard deviation (SD) and frequency (proportion) where appropriate
T treatment, TN treatment naïve
‡ p-value (comparison between control and treatment)
# p-value (comparison between control and treatment naïve)
Variables Total (n = 200) Control (n = 50) T (n = 75) ‡p-value TN (n = 75) #p-value
Age (years) 39.6 ± 0.8 40.5 ± 1.4 39.0 ± 1.3 0.4654 38.9 ± 1.4 0.412
Gender 0.4723 0.7169
 Male 96 (48.0%) 26 (52.0%) 34 (45.3%) 36 (48.0%)
 Female 104 (52.0%) 24 (48.0%) 41 (54.7%) 39 (52.0%)
Table 2 Biochemical profile of the study participants
Values are presented as mean ± standard deviation (SD) and frequency (proportion) where appropriate
UIBC unsaturated iron binding capacity, TIBC total iron binding capacity, AST aspartate aminotransferase, ALT alanine aminotransferase, T treatment, GGT gamma-
glutamyl transferase, TN treatment naïve
‡ p-value (comparison between control and treatment)
# p-value (comparison between control and treatment naïve)
Variables Total (n = 200) Control (N = 50) T (n = 75) ‡p-value TN (N = 75) #p-value
Markers of iron overload
 Serum iron (µmol/l) 37.2 ± 1.1 31.3 ± 1.8 33.5 ± 1.4 0.3519 44.9 ± 1.8 < 0.0001
 Serum UIBC (µmol/l) 60.9 ± 1.6 69.6 ± 2.1 66.2 ± 2.5 0.2846 40.0 ± 2.5 < 0.0001
 Serum TIBC (µmol/l) 95.2 ± 2.4 100.9 ± 3.7 99.6 ± 3.4 0.5374 84.9 ± 3.1 < 0.0001
 Serum ferritin (ng/ml) 92.1 ± 5.1 81.6 ± 7.5 94.3 ± 8.2 0.2827 97.0 ± 10.9 0.2956
 log10 (ferritin) 1.8 ± 0.0 1.8 ± 0.1 1.9 ± 0.0 0.5674 1.9 ± 0.0 0.3975
 Serum transferrin (g/l) 3.8 ± 0.1 4.02 ± 0.1 3.9 ± 0.1 0.3761 3.4 ± 0.1 < 0.0001
 % transferrin saturation 39.2 ± 0.8 31.01 ± 0.9 33.6 ± 1.0 0.3145 52.9 ± 1.6 < 0.0001
Markers of liver function
 Serum AST (U/l) 24.7 ± 0.9 20.9 ± 1.2 23.9 ± 1.2 0.0773 28.0 ± 1.8 0.0035
 Serum ALT (U/l) 17.9 ± 0.6 17.8 ± 1.4 17.4 ± 0.8 0.8240 18.5 ± 1.1 0.6570
 GGT (U/l) 29.3 ± 1.8 21.32 ± 1.3 29.7 ± 1.9 0.0503 36.98 ± 2.4 0.0418
 AST:ALT ratio 1.5 ± 0.0 1.29 ± 0.0 1.50 ± 0.1 0.0282 1.61 ± 0.1 0.0004
 log10ferrtin:AST ratio 0.087 ± 0.0 0.096 ± 0.0 0.084 ± 0.0 0.0448 0.080 ± 0.0 0.0113
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UIBC and STfR (p < 0.0001 each), as well as higher TIBC 
(p = 0.0026) and  log10ferritin (p = 0.0035) rather  than 
their female counterparts. There was no significant dif-
ference among gender with respect to the liver function 
parameters, albeit the males showed higher mean levels 
of AST, ALT and GGT. With the exception of the com-
parable means of  log10ferritn between the female treat-
ment group and the female controls, all gender-matched 
comparisons across the various groups were statistically 
significant (p < 0.05).
Additional file  1: Table  S1 shows the association 
between iron indices and liver function parameters 
among both treatment and treatment-naïve schizophre-
nia patients. There was a positive and significant corre-
lation between  log10ferritin and AST, and  log10ferritin 
and GGT in both treatments (r = 0.343; p = 0.003, and 
r = 0.502; p = 0.001 respectively) and treatment-naïve 
groups (r = 0.348; p = 0.002, and r = 0.614; p < 0.001 
respectively). Also, percentage transferrin saturation cor-
related significantly with GGT only, in the treatment-
naïve group (r = 0.667; p < 0.001), and ALT and GGT in 
the treatment group (r = 0.252; p = 0.030 and r = 0.646; 
p = 0.014 respectively). See Additional file 1.
Discussion
In this study, the females constituted 54.7% of the treat-
ment group. Similarly, in the treatment-naïve group, 
there were more females (52.0%) than males (48.0%). 
Owiredu et al. [5] also observed that higher prevalence of 
psychiatric disorders were associated with females than 
males in Ghana [5]. Moreover in a study by Oyane et al. 
[21], the female gender was more predisposed to factors 
of psychiatric disorders [21]. The increased female preva-
lence observed in the current study can be attributed to 
the fact that, women are emotionally and psychologically 
fragile in nature and are known to often internalize and 
brood over problems compared to men [22].
Consistent with the findings of Ikeda [23], this pre-
sent study observed significantly higher serum levels of 
iron and percentage transferrin saturation among the 
treatment-naïve group compared to the treatment and 
control groups [23]. Moreover, the lower levels of UIBC 
observed among the treatment psychiatric group and 
the significantly lower UIBC recorded for the treatment-
naïve group also confirms the findings of Ikeda [23], who 
observed similar levels among epileptic conditions com-
pared to their control counterpart [23].
In agreement with the fact that the liver is the main 
storage reserve of iron and is significantly affected by 
excess iron [8, 24], the treatment-naïve group in the cur-
rent study presented significantly higher AST and GGT 
levels compared to the control group. Significantly higher 
AST/ALT ratio was also associated with the treatment-
naïve patients compared to the controls, but the levels 
were comparable to the treatment group. AST/ALT ratio 
greater than 2:1 and increased GGT levels have been 
implicated in liver damage [25].
Numerous studies using experimental hepatic 
iron overload have identified iron-dependent oxi-
dative damage and associated impairment of 
Tables 3 Biochemical profile of study population in relation to gender
Values are presented as mean ± standard deviation (SD)
T treatment, TN treatment naïve
‡ p<0.05 for comparison between male control and male T or TN group)
# p < 0.05 for comparison between female control and female T or TN group
$ p<0.05 for comparison between male T and male TN group
$$ p<0.05 for comparison between male T male TN group
Parameter Control p-value T p-value TN p-value
Males (n = 26) Females 
(n = 24)
Male (n = 34) Female (n = 41) Male (n = 36) Female (n = 39)
Iron (µmol/l) 26.53 ± 2.8 25.66 ± 1.69 0.0921 ‡36.33 ± 2.01$ #30.82 ± 1.99$$ 0.0573 ‡52.68 ± 2.75 #35.85 ± 1.89 < 0.0001
UIBC (µmol/l) 42.12 ± 4.40 39.76 ± 3.35 0.0604 ‡26.46 ± 3.6$ #25.18 ± 2.99$$ 0.5290 ‡39.63 ± 4.02 #33.04 ± 5.34 < 0.0001
TIBC (µmol/l) 60.65 ± 5.7 59.03 ± 4.03 0.7190 ‡67.14 ± 2.65$ #61.03 ± 3.01$$ 0.7330 ‡75.96 ± 2.87 #63.86 ± 2.61 0.0026
log10ferritin 1.72 ± 0.05 1.71 ± 0.07 0.0807 ‡2.00 ± 0.04$ 1.72 ± 0.06$$ 0.0005 ‡1.97 ± 0.05 #1.76 ± 0.05 0.0035
STfR (µmol/l) 2.29 ± 0. 18 2.35 ± 0.13 0.0899 ‡4.12 ± 0.16$ #3.83 ± 0.21$$ 0.2977 ‡5.13 ± 0.23 #4.05 ± 0.12 < 0.0001
%T. saturation 44.88 ± 1.16 44.52 ± 2.64 0.9132 ‡34.97 ± 1.7$ #32.02 ± 1.34$$ 0.1092 ‡63.56 ± 1.76 #58.74 ± 2.64 0.1188
Markers of liver function
 AST (U/l) 17.92 ± 1.80 17.17 ± 1.01 0.0512 ‡23.03 ± 0.85$ #24.78 ± 2.00$$ 0.4558 ‡30.53 ± 3.21 #25.69 ± 1.66 0.1756
 ALT (U/l) 15.50 ± 2.07 14.79 ± 1.63 0.0668 ‡18.09 ± 1.17$ #16.88 ± 1.12$$ 0.4593 ‡19.31 ± 1.83 #17.82 ± 1.23 0.4967
 GGT 21.10 ± 1.6 20.31 ± 1.4 0.0701 ‡29.81 ± 1.9$ #28.12 ± 1.3$$ 0.6311 ‡36.81 ± 2.3 #35.21 ± 2.0 0.5571
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membrane-dependent functions of the mitochon-
dria, microsomes, and lysosomes [26, 27]. Thus iron-
induced lipid peroxidation occurs in hepatocytes and 
increases the risk of hepatocellular injury [28, 29]. 
Moreover, the current study recorded significantly 
lower log ferritin/AST ratio in both the treatment-
naïve and treatment groups compared to the control. 
These significantly lower ratios among both groups 
may be attributed to the likelihood of liver dysfunction 
secondary to iron overload [8, 30].
A previous retrospective review by Feifel and Young 
[15] reported increased plasma iron levels of greater 
than 170  μg/dl; transferrin saturation greater than 
50% and serum ferritin greater than 450 ng/ml among 
patients with bipolar disorder [15]. Iron dysregula-
tion and overload have also been implicated in Parkin-
son’s disease [31], Alzheimer’s disease and dementia 
[32, 33]. Compared to the control group, both males 
and females in the treatment group reported relatively 
higher mean levels of iron, transferrin saturation, ALT, 
GGT and AST, but lower levels of UIBC in the present 
study. With the exception of AST, ALT and GGT levels, 
a similar trend observed among the treatment-naïve 
group revealed significant differences (p < 0.001) in 
relation to gender. Abnormal serum ferritin (> 300 μg/l 
in men and > 120 μg/l in women), and transferrin satu-
ration (> 50%) have been reported by Cutler in a case 
study among psychiatric patients [34], which is consist-
ent with the findings in the current study.
A significant positive correlation between  log10ferritin 
and AST, and  log10ferritin and GGT was observed in 
both treatment and treatment-naïve groups. This par-
tially agrees with a previous study by Barut et  al. [35] 
which also reported a positive correlation between fer-
ritin and AST levels. This association has been impli-
cated in certain disease conditions such as liver damage 
[36], malignancy and infection [37]. Moreover, the cur-
rent study recorded a significant positive correlation 
between percentage transferrin saturation and GGT 
only, in the treatment-naïve group, and both ALT and 
GGT in the treatment group. The association of ferritin 
and transferrin saturation with the liver function mark-
ers suggests that iron metabolism may be associated 
with liver damage in mental illness [38].
Conclusion
Iron overload is common among schizophrenia patients 
in Ghana, and the iron indices are associated with AST/
ALT ratio and log Ferritin:AST ratio within treatment-
naïve patients. The response of these biological mark-
ers has clinical implication on liver performance; thus 
a possible future risk of fibrosis, mutagenesis and 
carcinogenesis. This emerging syndemic among schizo-
phrenia patients in Ghana therefore necessitates base-
line and periodic medical assessment of iron indices as 
standard components in the management plans for psy-
chiatric patients.
Limitations
The current study could not provide information on 
other potential confounding factors such as Body Mass 
Index (BMI), menstruation and diet patterns, and hence 
should be considered in future investigations” With the 
smaller sample size obtained in this case–control study, 
only a temporal relationship between iron overload and 
liver dysfunctions can be established. A further larger 
longitudinal study is warranted to validate this syn-
demic relationship among schizophrenics.
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 Additional file 1: Table S1. Partial Pearson correlation between Iron 
markers and liver function markers among study participants.
Abbreviations
UIBC: unsaturated iron binding capacity; TIBC: total iron binding capacity; 
AST: aspartate transminase; ALT: alanine transminase; GGT : gamma-glutamyl 
transferase.
Acknowledgements
The authors wish to thank the students and authorities of the various faculties 
and departments.
Authors’ contributions
WKBAO and PKB contributed to the conception of the research idea, design-
ing data analysis and interpretation. YO and EFL contributed to the paper 
drafting and revision. COO and CO revised the manuscript and edited the text. 
EOA, EA and SD contributed in data analyses, interpretation and proofreading. 
All authors read and approved the final manuscript.
Funding
No funding was obtained for this study.
Availability of data and materials
All data generated or analyzed during this study are included in this article 
and its Additional file.
Ethics approval and consent to participate
All procedures performed in this study were in accordance with the Helsinki 
Declaration. The study was approved by the Committees on Human Research 
Publication and Ethics (CHRPE) of the Kwame Nkrumah University of Science 
and Technology (KNUST) and the Komfo Anokye Teaching Hospital (KATH), 
Kumasi. Written informed consent was obtained from each participant 
through their legal family member after explaining the aim of the project, and 
the liberty to participate or not.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Page 6 of 6Owiredu et al. BMC Res Notes          (2019) 12:802 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Author details
1 Department of Molecular Medicine, KNUST School of Medicine and Den-
tistry, Kwame Nkrumah University of Science and Technology (KNUST), 
Kumasi, Ghana. 2 School of Medical and Health Sciences, Edith Cowan 
University (ECU), Joondalup, Perth-WA, Australia. 3 Department of Physician 
Assistance, Faculty of Health and Allied Sciences, Garden City University Col-
lege (GCUC), Kenyasi, Kumasi, Ghana. 4 Department of Medical Laboratory 
Technology, Faculty of Allied Health Science, KNUST, Kumasi, Ghana. 
Received: 28 October 2019   Accepted: 6 December 2019
References
 1. World Health Organization, W. Prevention of mental disorders: effective 
interventions and policy options: summary report; 2004.
 2. WHO. A very progressive mental health law-Ghana. Mental Health 
Improvements for Nations Development (MHIND). 2007. Department of 
Mental Health and Substance Abuse, Geneva.
 3. Sikanartey T, Eaton WW. Prevalence of schizophrenia in the Labadi district 
of Ghana. Acta Psychiatr Scand. 1984;69(2):156–61.
 4. Turkson S, Asante K. Psychiatric disorders among offender patients in the 
Accra Psychiatric Hospital. West Afr J Med. 1997;16(2):88–92.
 5. Owiredu W, et al. Hyperlipidaemia following treatment with antipsychotic 
medications. J Ghana Sci Assoc. 2009. https ://doi.org/10.4314/jgsa.v11i2 
.50941 .
 6. Robson D, Gray R. Serious mental illness and physical health problems: a 
discussion paper. Int J Nurs Stud. 2007;44(3):457–66.
 7. Sokal J, et al. Comorbidity of medical illnesses among adults with serious 
mental illness who are receiving community psychiatric services. J Nerv 
Ment Dis. 2004;192(6):421–7.
 8. Pietrangelo A. Iron and the liver. Liver Int. 2016;36:116–23.
 9. Dooley J, Worwood M. Guidelines on diagnosis and therapy: genetic 
haemochromatosis. London: British Committee for Standards in Haema-
tology; 2000. p. 1–33.
 10. Baptista-González H, et al. Evaluation of iron overload in healthy adult 
residents of Mexico City. Arch Med Res. 2005;36(2):142–7.
 11. Klipstein-Grobusch K, et al. Serum ferritin and risk of myocardial infarction 
in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69(6):1231–6.
 12. Tuomainen T-P, et al. Association between body iron stores and the risk of 
acute myocardial infarction in men. Circulation. 1998;97(15):1461–6.
 13. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among 
US adults. Diabetes Care. 1999;22(12):1978–83.
 14. Armengou A, Davalos A. A review of the state of research into the role of 
iron in stroke. J Nutr Health Aging. 2002;6(3):207–8.
 15. Feifel D, Young CW. Iron overload among a psychiatric outpatient popula-
tion. J Clin Psychiatry. 1997;58(2):74–8.
 16. Ayd FJ. Lexicon of psychiatry, neurology, and the neurosciences. Balti-
more: Lippincott Williams & Wilkins; 2000.
 17. Cutler P. Iron overload in psychiatric illness. Am J Psychiatry. 
1991;148(1):147–8.
 18. Essuman EE. Study of trace elements levels and oxidative stress in 
Ghanaian psychiatric patients receiving medication and treatment naive 
patients. 2012.
 19. Vernet M. Immunochemical assay of transferrin and iron saturation in 
serum. Clin Chem. 1993;39(11):2352–3.
 20. Gambino R, et al. The relation between chemically measured total iron-
binding capacity concentrations and immunologically measured trans-
ferrin concentrations in human serum. Clin Chem. 1997;43(12):2408–12.
 21. Øyane NM, et al. Seasonal variations in mood and behaviour associated 
with gender, annual income and education: the Hordaland Health Study. 
Eur J Epidemiol. 2005;20(11):929–37.
 22. Gore-Felton C, et al. Relationships of sexual, physical, and emotional 
abuse to emotional and behavioral problems among incarcerated ado-
lescents. J Child Sex Abuse. 2002;10(1):73–88.
 23. Ikeda M. Iron overload without the C282Y mutation in patients with 
epilepsy. J Neurol Neurosurg Psychiatry. 2001;70(4):551–3.
 24. Pelusi S, Valenti L, Fargion S. Oxidative stress and hepatic iron overload, in 
studies on hepatic disorders. New York: Springer; 2015. p. 345–56.
 25. Berger SH, Ford RM. Alcoholic liver disease and nonalcoholic fatty liver 
disease. Sitaraman and Friedman’s essentials of gastroenterology. Hobo-
ken: Wiley; 2017. p. 211–25.
 26. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free 
radical-mediated process? Hepatology. 1990;11(1):127–37.
 27. Philippe MA, Ruddell RG, Ramm GA. Role of iron in hepatic fibrosis: one 
piece in the puzzle. World J Gastroenterol. 2007;13(35):4746.
 28. Olynyk JK, et al. A population-based study of the clinical expression of the 
hemochromatosis gene. N Engl J Med. 1999;341(10):718–24.
 29. Bacon BR, et al. Diagnosis and management of hemochromatosis: 2011 
practice guideline by the American Association for the Study of Liver 
Diseases. Hepatology. 2011;54(1):328–43.
 30. Ünlüsoy Aksu A, et al. Iron overload in the liver of 2 children: nonalcoholic 
steatohepatitis and juvenile hemochromatosis. J Pediatr Hematol Oncol. 
2017;39(6):466–9.
 31. Chen L-L, et al. Iron dysregulation in parkinson’s disease: focused on the 
autophagy-lysosome pathway. ACS Chem Neurosci. 2018;10(2):863–71.
 32. Hosking DE, et al. More evidence is neededIron, incident cognitive 
decline and dementia a systematic review. Ther Adv Chronic Dis. 
2018;9(12):241–56.
 33. Vance E, et al. Failure to detect synergy between variants in transferrin 
and hemochromatosis and Alzheimer’s disease in a large cohort. bioRxiv. 
2019:649962.
 34. Cutler P. Iron overload and psychiatric illness. Can J Psychiatry. 
1994;39(1):8–11.
 35. Barut S, et al. Increased serum ferritin levels in patients with Crimean-
Congo hemorrhagic fever: can it be a new severity criterion? Int J Infect 
Dis. 2010;14(1):e50–4.
 36. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron 
overload and with acute and chronic liver diseases. Gastroenterology. 
1975;68(3):525–33.
 37. Worwood M, Cook JD. Serum ferritin. CRC Crit Rev Clin Lab Sci. 
1979;10(2):171–204.
 38. Milic S, et al. The role of iron and iron overload in chronic liver disease. 
Med Sci Monit. 2016;22:2144.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
